Pediatrix Medical Group Future Growth
Future criteria checks 3/6
Pediatrix Medical Group's revenue is forecast to decline at 0.2% per annum while its annual earnings are expected to grow at 95.3% per year. EPS is expected to grow by 90.9% per annum. Return on equity is forecast to be 14.7% in 3 years.
Key information
95.3%
Earnings growth rate
90.9%
EPS growth rate
| Healthcare earnings growth | 20.9% |
| Revenue growth rate | -0.2% |
| Future return on equity | 14.7% |
| Analyst coverage | Good |
| Last updated | 05 Nov 2024 |
Recent future growth updates
Recent updates
Pediatrix Medical Group: The Business Is Turning
Nov 18Pediatrix Medical Group, Inc. (NYSE:MD) Shares Fly 27% But Investors Aren't Buying For Growth
Nov 06
Here's Why Pediatrix Medical Group (NYSE:MD) Has A Meaningful Debt Burden
Oct 19We Like These Underlying Return On Capital Trends At Pediatrix Medical Group (NYSE:MD)
Sep 28Improved Revenues Required Before Pediatrix Medical Group, Inc. (NYSE:MD) Stock's 32% Jump Looks Justified
Aug 07Does Pediatrix Medical Group (NYSE:MD) Have A Healthy Balance Sheet?
Jun 19Pediatrix Medical Group (NYSE:MD) Has Some Way To Go To Become A Multi-Bagger
May 10Pediatrix Medical Group, Inc.'s (NYSE:MD) Price Is Right But Growth Is Lacking
Mar 29Pediatrix Medical Group, Inc.'s (NYSE:MD) Intrinsic Value Is Potentially 100% Above Its Share Price
Jan 10Pediatrix Medical Group, Inc.'s (NYSE:MD) Earnings Are Not Doing Enough For Some Investors
Dec 25Is Pediatrix Medical Group (NYSE:MD) A Risky Investment?
Nov 14Is It Time To Consider Buying Pediatrix Medical Group, Inc. (NYSE:MD)?
Oct 13Does Pediatrix Medical Group (NYSE:MD) Have A Healthy Balance Sheet?
Aug 09Pediatrix: Unable To Deploy Capital Tied Up In Cash Conversion Cycle, Reiterate Hold
Aug 08At US$14.21, Is Pediatrix Medical Group, Inc. (NYSE:MD) Worth Looking At Closely?
Jul 03The Returns At Pediatrix Medical Group (NYSE:MD) Aren't Growing
Jun 08Pediatrix Medical Group (NYSE:MD) Has A Somewhat Strained Balance Sheet
Apr 26Is Now An Opportune Moment To Examine Pediatrix Medical Group, Inc. (NYSE:MD)?
Feb 20Pediatrix Medical Group Q4 2022 Earnings Preview
Feb 16Is Pediatrix Medical Group (NYSE:MD) A Risky Investment?
Jan 12Pediatrix: RCM Overhang Now Too Heavy, Revise To Hold
Dec 22Return Trends At Pediatrix Medical Group (NYSE:MD) Aren't Appealing
Dec 20Pediatrix appoints James Swift as chief executive officer
Dec 15Why Pediatrix Medical Group, Inc. (NYSE:MD) Could Be Worth Watching
Nov 05Pediatrix Medical Group GAAP EPS of $0.37 misses by $0.11, revenue of $489.92M misses by $21.54M
Nov 03Pediatrix: These 5 Graphs Suggest It's A Buy
Sep 29Here's Why Pediatrix Medical Group (NYSE:MD) Can Manage Its Debt Responsibly
Sep 13Here's What To Make Of Pediatrix Medical Group's (NYSE:MD) Decelerating Rates Of Return
Aug 29Why Pediatrix Medical Group, Inc. (NYSE:MD) Could Be Worth Watching
Jul 27Pediatrix: Seeking 46% Return Objective As Speculative Buy
Jul 14MEDNAX, Inc. (NYSE:MD) Shares Could Be 47% Below Their Intrinsic Value Estimate
Jun 24MEDNAX (NYSE:MD) Has A Pretty Healthy Balance Sheet
May 25Return Trends At MEDNAX (NYSE:MD) Aren't Appealing
Apr 20MEDNAX, Inc.'s (NYSE:MD) Intrinsic Value Is Potentially 96% Above Its Share Price
Mar 08MEDNAX (NYSE:MD) Seems To Use Debt Quite Sensibly
Feb 15Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 1,982 | 103 | N/A | N/A | 5 |
| 12/31/2025 | 1,942 | 115 | 131 | 162 | 7 |
| 12/31/2024 | 1,998 | -17 | 102 | 136 | 7 |
| 9/30/2024 | 2,007 | -254 | 115 | 143 | N/A |
| 6/30/2024 | 2,002 | -252 | 100 | 131 | N/A |
| 3/31/2024 | 1,999 | -71 | 81 | 113 | N/A |
| 12/31/2023 | 1,995 | -60 | 104 | 137 | N/A |
| 9/30/2023 | 2,012 | 88 | 133 | 167 | N/A |
| 6/30/2023 | 1,995 | 95 | 139 | 170 | N/A |
| 3/31/2023 | 1,981 | 98 | 134 | 164 | N/A |
| 12/31/2022 | 1,972 | 63 | 137 | 167 | N/A |
| 9/30/2022 | 1,957 | 79 | 89 | 112 | N/A |
| 6/30/2022 | 1,960 | 82 | 63 | 90 | N/A |
| 3/31/2022 | 1,947 | 82 | 31 | 61 | N/A |
| 12/31/2021 | 1,911 | 108 | 44 | 77 | N/A |
| 9/30/2021 | 1,829 | 72 | -15 | 21 | N/A |
| 6/30/2021 | 1,797 | 38 | 99 | 129 | N/A |
| 3/31/2021 | 1,739 | 14 | 236 | 264 | N/A |
| 12/31/2020 | 1,734 | -10 | 176 | 205 | N/A |
| 9/30/2020 | 1,776 | -4 | 326 | 352 | N/A |
| 6/30/2020 | 1,770 | 11 | 321 | 341 | N/A |
| 3/31/2020 | 1,678 | 1 | 261 | 284 | N/A |
| 12/31/2019 | 1,780 | 42 | 338 | 358 | N/A |
| 9/30/2019 | 2,210 | 94 | 331 | 351 | N/A |
| 6/30/2019 | 2,603 | 143 | 292 | 320 | N/A |
| 3/31/2019 | 3,145 | 221 | 296 | 324 | N/A |
| 12/31/2018 | 1,723 | 122 | 297 | 314 | N/A |
| 9/30/2018 | 3,477 | 333 | 303 | 346 | N/A |
| 6/30/2018 | 3,497 | 337 | N/A | 417 | N/A |
| 3/31/2018 | 3,475 | 326 | N/A | 420 | N/A |
| 12/31/2017 | 3,253 | 305 | N/A | 498 | N/A |
| 9/30/2017 | 3,378 | 262 | N/A | 447 | N/A |
| 6/30/2017 | 3,337 | 293 | N/A | 443 | N/A |
| 3/31/2017 | 3,266 | 312 | N/A | 455 | N/A |
| 12/31/2016 | 3,183 | 325 | N/A | 444 | N/A |
| 9/30/2016 | 3,094 | 340 | N/A | 417 | N/A |
| 6/30/2016 | 2,988 | 334 | N/A | 393 | N/A |
| 3/31/2016 | 2,893 | 336 | N/A | 389 | N/A |
| 12/31/2015 | 2,780 | 336 | N/A | 369 | N/A |
| 9/30/2015 | 2,689 | 332 | N/A | 443 | N/A |
| 6/30/2015 | 2,593 | 327 | N/A | 431 | N/A |
| 3/31/2015 | 2,512 | 322 | N/A | 419 | N/A |
| 12/31/2014 | 2,439 | 317 | N/A | 423 | N/A |
| 9/30/2014 | 2,356 | 308 | N/A | 383 | N/A |
| 6/30/2014 | 2,284 | 299 | N/A | 382 | N/A |
| 3/31/2014 | 2,218 | 289 | N/A | 374 | N/A |
| 12/31/2013 | 2,154 | 281 | N/A | 405 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MD is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.6%).
Earnings vs Market: MD is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: MD is expected to become profitable in the next 3 years.
Revenue vs Market: MD's revenue is expected to decline over the next 3 years (-0.2% per year).
High Growth Revenue: MD's revenue is forecast to decline over the next 3 years (-0.2% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: MD's Return on Equity is forecast to be low in 3 years time (14.7%).